Current achievements in the production of complex biopharmaceuticals with moss bioreactors

@article{Decker2008CurrentAI,
  title={Current achievements in the production of complex biopharmaceuticals with moss bioreactors},
  author={Eva L. Decker and Ralf Reski},
  journal={Bioprocess and Biosystems Engineering},
  year={2008},
  volume={31},
  pages={3-9}
}
  • E. Decker, R. Reski
  • Published 2008
  • Biology, Engineering
  • Bioprocess and Biosystems Engineering
Transgenic plants are promising alternatives for the low-cost and safe pathogen-free production of complex recombinant pharmaceutical proteins (molecular farming). Plants as higher eukaryotes perform posttranslational modifications similar to those of mammalian cells. However, plant-specific protein N-glycosylation was shown to be immunogenic, a fact that represents a drawback for many plant systems in biopharmaceutical production. The moss Physcomitrella patens offers unique properties as a… 
View on Springer
plant-biotech.net
100 Citations
Highly Influential Citations
3
Background Citations
47
Methods Citations
3

Figures from this paper

100 Citations

Citation Type

Citation Type

Glycoprotein production in moss bioreactors
TLDR
Therapeutic antibodies produced in P. patens lines with non-immunogenic optimized glycan structures exhibited antibody-dependent cellular cytotoxicity superior to the same molecules synthesized in mammalian cell lines.
Glyco-engineering for biopharmaceutical production in moss bioreactors
TLDR
The glyco-engineering approaches to avoid non-human N- and O-glycosylation on target proteins produced in moss bioreactors are discussed.
PLANTS AS BIOFACTORIES FOR THE PRODUCTION OF BIOPHARMACEUTICALS: A BRIEF REVIEW
TLDR
Safe, cost effective and considerable high level of recombinant protein production with the ability to properly fold and assemble eukaryotic proteins makes it an alternative competitive system with microbial and mammalian hosts.
The production of biopharmaceuticals in plant systems.
Plants as Bioreactors- A Review
TLDR
This review tries to give an update of plant produced recombinant proteins, the future and limitations of these systems, which have shown immunogenicity, several have been shown to work effectively in animal models.
Plant biofarming: Novel insights for peptide expression in heterologous systems
TLDR
Plant biofarming in the moss Physcomitrella patens is brought into discussion, as a cost‐effective and efficient approach in the production of more complex heterologous proteins, given the fact that its glycosylation pattern can be engineered to avoid allergenicity to humans.
Advancements in plant transgenomics approach for the biopharmaceutics and vaccines production
Advances in plant molecular farming.
The potential of Physcomitrella patens as a platform for the production of plant-based vaccines
TLDR
This opinion paper analyzes the possibilities of using P. patens for the production of oral vaccines and presents some specific cases where its use may represent significant progress in the field of plant-based vaccine development.
Gene Targeting for Precision Glyco-Engineering: Production of Biopharmaceuticals Devoid of Plant-Typical Glycosylation in Moss Bioreactors.
TLDR
The methods which are effective for creating gene targeting constructs and transgenic moss lines are described as well as confirming successful homologous integration of the constructs and modification of target gene expression.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
The moss bioreactor.
A fast and flexible PEG-mediated transient expression system in plants for high level expression of secreted recombinant proteins.
Plant cell cultures for the production of recombinant proteins
TLDR
Although no recombinant proteins have yet been produced commercially using plant cell cultures, there have been many proof-of-principle studies and several companies are investigating the commercial feasibility of such production systems.
Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans.
TLDR
The modifications described here represent the key step towards the generation of moss lines suitable for the production of plant-made glycosylated biopharmaceuticals with nonallergenic N-glycans.
Glyco-engineering of moss lacking plant-specific sugar residues.
TLDR
The combined knockout/knockin approach presented here, leads to a new generation of engineered moss and towards the safe and flexible production of correctly processed pharmaceutical proteins with humanised N-glycosylation profiles.
Recombinant expression systems in the pharmaceutical industry
  • F. Schmidt
  • Biology
    Applied Microbiology and Biotechnology
  • 2004
TLDR
To fully exploit the secretory capacity of fungal species, a deeper understanding of their posttranslational modification physiology will be necessary to steer the degree and pattern of glycosylation, which influences both folding and secretion efficiency.
Use of endogenous signal sequences for transient production and efficient secretion by moss (Physcomitrella patens) cells
TLDR
The supremacy of moss secretion signals over the utilised heterologous ones within the moss-bioreactor system is reported on, suggesting translational inhibition during the signal recognition particle-cycle (SRP-cycle) as the most probable of several possible explanations for the decreased extracellular accumulation with the human signals.
Opportunities for recombinant antigen and antibody expression in transgenic plants--technology assessment.
N-glycosylation of recombinant pharmaceutical glycoproteins produced in transgenic plants: towards an humanisation of plant N-glycans.
TLDR
The number of therapeutic proteins successfully produced in plants is steadily increasing and is expected to grow even more rapidly in the future, while strategies to humanise plant N-glycans are now developed.
Protein modifications in the plant secretory pathway: current status and practical implications in molecular pharming.
...
1
2
3
4
5
...